Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. COVID-19 Right
  3. bamlanivimab and etesevimab together Right
  4. What were the common treatment emergent adverse events with bamlanivimab and etesevimab treatment?
Search Bamlanivimab and etesevimab together (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

bamlanivimab and etesevimab together

bamlanivimab and etesevimab together

700mg/1400mg

HCP Fact Sheet | Patient & Caregiver Fact Sheet | FDA Authorization Letter

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What were the common treatment emergent adverse events with bamlanivimab and etesevimab treatment?

In the BLAZE-1 trial, most treatment-emergent adverse events were mild to moderate in severity; no deaths were reported in the bamlanivimab/ etesevimab treatment arm.

US_cFAQ_BAM_ETE101_OVERVIEW_TEAES_COVID-19
US_cFAQ_BAM_ETE101_OVERVIEW_TEAES_COVID-19
en-US

Bamlanivimab and Etesevimab Emergency Use Authorization

Bamlanivimab and etesevimab have not been approved, but have only been authorized for emergency use by Food and Drug Administration (FDA) for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the bamlanivimab and etesevimab under Section 564(b)(1)(C) of the Act, 21 U.S.C. 360bbb-3, unless the authorization is terminated or revoked sooner.1,2   

Bamlanivimab and etesevimab are authorized to be administered together in adults and pediatric patients, including neonates, who are at high risk for progression to severe coronavirus disease 2019 (COVID-19), including hospitalization or death for

  • the treatment of mild to moderate COVID-19, or
  • post-exposure prophylaxis of COVID-19.1,2    

For information on the authorized use of bamlanivimab and etesevimab together and mandatory requirements under the emergency use authorization (EUA), please review the FDA Letter of Authorization, Fact Sheet for Healthcare Providers, and Fact Sheet for Patients/Caregivers at www.LillyAntibody.com. 1,2    

Bamlanivimab and Etesevimab Fact Sheet for Healthcare Providers

Warnings

There are limited clinical data available for bamlanivimab and etesevimab. Serious and unexpected adverse events may occur that have not been previously reported with use of bamlanivimab and etesevimab together.1

Clinical Worsening After Bamlanivimab and Etesevimab Administration

Clinical worsening of COVID-19 after administration of bamlanivimab and etesevimab together has been reported and may include signs or symptoms of

  • fever
  • hypoxia or increased respiratory difficulty
  • arrhythmia (e.g., atrial fibrillation, sinus tachycardia, bradycardia)
  • fatigue, and
  • altered mental status.1

Some of these events required hospitalization. It is not known if these events were related to bamlanivimab and etesevimab use or were due to progression of COVID-19.1

Side Effects

Adverse events have been reported with bamlanivimab and etesevimab.1

Additional AEs associated with bamlanivimab and etesevimab, some of which may be serious, may become apparent with more widespread use.1

Overall Safety Summary

Clinical Trials Experience

Adults (≥18 Years) and Pediatric Patients (<18 Years and Weighing at Least 40 kg)

The safety of bamlanivimab administered with etesevimab is primarily based on exposure of approximately 1400 ambulatory (nonhospitalized) subjects who received doses of bamlanivimab and etesevimab together, at the recommended dose or higher, in BLAZE-1 and BLAZE-4 (see BLAZE Clinical Trial Designs).1

BLAZE-1 is a phase 2/3, randomized, double-blind, placebo-controlled clinical trial studying bamlanivimab and etesevimab administered together for the treatment of subjects with mild to moderate COVID-19. Thirty-four pediatric patients (ages 12 to <18 years and weighing at least 40 kg) were included in the phase 3 portion of BLAZE-1 (14 received placebo, 14 received the authorized dose or a higher dose for their age, and 6 received a lower dose than authorized for their age). In the phase 3 portion of the trial, enrolled participants had at least one risk factor for the development of severe COVID-19 illness.1

BLAZE-4 is a phase 2, randomized, double-blind, placebo-controlled clinical trial studying bamlanivimab and etesevimab for the treatment of subjects with mild to moderate COVID-19. Subjects ≥65 years old or with a body mass index (BMI) ≥35 were excluded from enrollment.1

In clinical trials, approximately 4000 subjects have received bamlanivimab (either alone or with etesevimab) at doses ranging from 700 to 7000 mg. Bamlanivimab and etesevimab at the authorized doses of 700 mg and 1400 mg have been administered together to approximately 800 subjects in clinical trials.1

The following adverse reactions (i.e., adverse events assessed as causally related) have been observed in those who have received bamlanivimab and etesevimab together at the authorized dose or higher:1

  • anaphylaxis (n=1, 0.07%)
  • infusion-related reactions (n=16, 1.1%)

In the case of anaphylaxis and serious infusion-related reactions, all infusions were stopped, and treatment was administered. One case required epinephrine. All events resolved.1

The most common treatment-emergent adverse events in the bamlanivimab and etesevimab treatment group in BLAZE-1 and BLAZE-4 included nausea, dizziness, and pruritus. No treatment-emergent adverse events occurred in more than 1% of participants and the rates were comparable in the treatment and placebo groups.1

Pediatric Patients (0 to <18 Years)

The total number of pediatric patients was 125. In addition to the 34 pediatric patients (aged 12 to <18 years and weighing at least 40 kg) enrolled in the phase 3 portion of BLAZE-1, an open-label pediatric addendum to BLAZE-1 enrolled

  • 40 patients aged 12 to <18
  • 36 patients aged 6 to <12
  • 10 patients aged 2 to <6, and
  • 5 patients aged 0 to <2.1

All pediatric patients had at least one risk factor for the development of severe COVID-19 illness.1

Pediatric patients weighing 8.6 kg to <40 kg received doses of bamlanivimab and etesevimab that were adjusted for their body weight, to achieve the same exposures as adults and adolescents receiving the authorized dose of 700 mg and 1400 mg, respectively.1

The adverse drug reaction profile in pediatric patients is consistent with the established profile.1

Bamlanivimab and Etesevimab Available Clinical Data

The information presented in the sections below contain data on unauthorized doses of bamlanivimab and etesevimab administered together. Please see the enclosed Fact Sheet for authorized dosing information.

Clinical Trial Design Overview

BLAZE-1 is a phase 2/3 randomized, double-blind, placebo-controlled trial evaluating bamlanivimab alone and together with etesevimab, in non-hospitalized patients with mild to moderate COVID-19.3-5

BLAZEa Clinical Trial Designs3-7

 

BLAZE-1 Phase 2 (NCT04427501)

BLAZE-1 Phase 3 (NCT04427501)

BLAZE-4 Phase 2 (NCT04634409)

Design

Randomized, double-blind, placebo-controlled trial in non-hospitalized patients with mild to moderate COVID-19

Randomized, double-blind, placebo-controlled trial in non-hospitalized patients with mild to moderate COVID-19 and at least 1 risk factorb for developing severe COVID-19 illness

Randomized, double-blind, placebo-controlled trial in non-hospitalized patients with mild to moderate COVID-19 illness 

Primary Endpoint

Change from baseline to day 11 in SARS-CoV-2 viral load

Percentage of participants who experience COVID-related hospitalization or death of any cause through day 29

Percentage of patients with SARS-CoV-2 viral load greater than 5.27 at day 7

Treatment arms included in analyses

Patients randomized to IV infusion of

  • bamlanivimab alone 700 mg (n=101), 2800 mg (n=107), or 7000 mg (n=101)
  • bamlanivimab 2800 mg and etesevimab 2800 mg together (n=112), or
  • placebo (n=156)

Patients randomized to IV infusion of

  • bamlanivimab 2800 mg and etesevimab 2800 mg together (n=518), or
  • placebo (n=517)

Patients randomized to IV infusion of

  • bamlanivimab 700 mg and etesevimab 1400 mg together (n=511), or
  • placebo (n=258)

Patients 18-64 years old randomized to IV infusion of

  • bamlanivimab 700 mg alone 
  • bamlanivimab and etesevimab together, dosed at
    • BAM 700 mg + ETE 1400 mg 
    • BAM 2800 mg + ETE 2800mg
  • bamlanivimab and VIR-7831 together
  • LY-CoV1404 alone
  • bamlanivimab, etesevimab, and LY-CoV1404 together
  • placebo

Abbreviations: BAM = bamlanivimab; BMI = body mass index; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; COVID-19 = coronavirus disease 2019; CVD = cardiovascular disease; ETE = etesevimab; IV = intravenous; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

aBLAZE clinical trials are ongoing studies, outcomes measures, inclusion/exclusion criteria, and eligibility may change throughout the study.

bRisk factors include: ≥ 65 years of age, BMI ≥ 35, CKD, type 1 or type 2 diabetes, immunosuppressive disease, receiving immunosuppressive treatment; ≥ 55 years of age AND have a history of CVD, or hypertension, or COPD or other chronic respiratory disease; 12-17 years of age AND satisfy at least one of the following at the time of screening: BMI ≥85th percentile for their age and gender based on CDC growth charts, sickle cell disease, congenital or acquired heart disease, neurodevelopmental disorders (for example, cerebral palsy), medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation not related to COVID-19), asthma or reactive airway or other chronic respiratory disease, type 1 or type 2 diabetes, immunosuppressive disease, or currently receiving immunosuppressive treatment.

Baseline Demographics and Disease Characteristics

Baseline demographics and disease characteristics were well balanced across treatment groups for each of the studies.1BLAZE Clinical Trials Baseline Demographics and Disease Characteristics provides information by study.

BLAZE Clinical Trials Baseline Demographics and Disease Characteristics1

 

BLAZE-1 Phase 2

BLAZE-1 Phase 3

BLAZE-4 Phase 2

Median age, years

45

56

39

≥ 65 years old

12%

31%

1%

Female

55%

52%

50%

White

89%

87%

87%

Hispanic or Latino

43%

29%

29%

Black or African American

6%

8%

6%

High-risk for severe COVID-19 illnessa

42%

100%

8%

Mild COVID-19

78%

77%

84%

Moderate COVID-19

22%

23%

16%

Mean duration of symptoms, days

5 

4

4

Mean viral load by CT

24

24

25

Abbreviations: BMI = body mass index; CKD = chronic kidney disease; COVID-19 = coronavirus disease 2019; CT = cycle threshold.

aHigh risk is defined as patients who meet at least one of the following criteria: BMI ≥35, CKD, diabetes, immunosuppressive disease, receiving immunosuppressive treatment, ≥65 years old, ≥55 years old AND have cardiovascular disease, OR hypertension, OR chronic obstructive pulmonary disease/other chronic respiratory disease. Are 12 – 17 years of age AND have BMI ≥85th percentile for their age and gender based, OR sickle cell disease, OR congenital or acquired heart disease, OR neurodevelopmental disorders, OR a medical-related technological dependence, OR asthma, reactive airway or other chronic respiratory disease that requires daily medication for control.

Bamlanivimab and Etesevimab: Summary of Safety Results

BLAZE-1 Phase 3 Safety Data

Treatment-emergent Adverse Events Reported in ≥ 2 Patients Treated with Bamlanivimab and Etesevimab presents reported TEAEs from an integrated safety analysis set of pooled data from BLAZE-1 and BLAZE-4 (with data through March 12, 2021) and included patients treated with 

  • bamlanivimab and etesevimab at the authorized doses of 700 mg and 1400 mg or higher (N=1400), or
  • placebo (N=985).8
Treatment-emergent Adverse Events Reported in ≥ 2 Patients Treated with Bamlanivimab and Etesevimab8

MedDRA System Organ Class

Preferred Term 

Placebo (N=985) 
n (%)

BAM+ETE (N=1400)a
n (%)

Gastrointestinal disorders

20 (2.0)

32 (2.3) 

Nausea

6 (0.6)

12 (0.9)

Gastroesophageal reflux disease

1 (0.1)

5 (0.4)

Vomiting 

3 (0.3)

5 (0.4)

Constipation 

3 (0.3)

3 (0.2)

Diarrhea

3 (0.3)

3 (0.2)

Abdominal pain 

2 (0.2)

2 (0.1)

Dyspepsia

1 (0.1)

2 (0.1) 

Nervous System disorders

16 (1.6)

27 (1.9)

Dizziness

4 (0.4)

11 (0.8)

Headache

1 (0.1)

3 (0.2)

Paresthesia

4 (0.4)

3 (0.2)

Dysgeusia

1 (0.1)

2 (0.1)

Presyncope

0

2 (0.1)

Sciatica

0

2 (0.1)

Syncope

1 (0.1)

2 (0.1)

Tremor

0

2 (0.1)

Infections and Infestations

22 (2.2)

25 (1.8)

Urinary Tract infections

2 (0.2)

7 (0.5)

Pneumonia

3 (0.3)

2 (0.1)

Sinusitis

2 (0.2)

2 (0.1)

Skin and Subcutaneous Tissue disorders

16 (1.6)

24 (1.7) 

Rash

6 (0.6)

9 (0.6)

Pruritus 

1 (0.1)

8 (0.6)

Urticaria 

1 (0.1)

4 (0.3)

General disorders and administration site conditions

9 (0.9)

17 (1.2) 

Pyrexia

0

4 (0.3)

Chest discomfort

0

3 (0.2)

Extravasation 

0

3 (0.2) 

Investigations

8 (0.8)

17 (1.2)

Liver function test increased 

3 (0.3)

6 (0.4)

C-reactive protein increased

1 (0.1)

3 (0.2)

Lipase increased 

1 (0.1)

2 (0.1)

Respiratory, thoracic and mediastinal disorders 

7 (0.7)

16 (1.1)

Rhinalgia

0

3 (0.2)

Asthma

1 (0.1) 

2 (0.1) 

Oropharyngeal pain 

0

2 (0.1) 

Sinus congestion 

1 (0.1) 

2 (0.1) 

Injury, poisoning and procedural complications

3 (0.3)

15 (1.1)

Fall 

1 (0.1)

3 (0.2)

Infusion related reactions 

0

3 (0.2)

Skin laceration 

0

2 (0.1)

Metabolism and nutrition disorders

8 (0.8)

14 (1.0)

Hyperglycemia 

0

2 (0.1)

Hyperlipidemia

1 (0.1)

2 (0.1) 

Type 2 diabetes mellitus

1 (0.1)

2 (0.1) 

Musculoskeletal and connective tissue disorders

12 (1.2)

10 (0.7)

Arthralgia 

2 (0.2)

3 (0.2) 

Back pain 

2 (0.2)

2 (0.1)

Muscular weakness 

0

2 (0.1) 

Vascular disorders 

3 (0.3)

8 (0.6) 

Hypertension 

2 (0.2)

4 (0.3)

Cardiac disorders

5 (0.5)

6 (0.4) 

Acute myocardial infarction

0

2 (0.1) 

Blood and lymphatic system disorders

2 (0.2)

5 (0.4) 

Anemia 

0

3 (0.2) 

Neutropenia 

0

2 (0.1)

Abbreviations: BAM = Bamlanivimab; ETE= Etesevimab; MedDRA = Medical Dictionary for Regulatory Activities

aDoses of bamlanivimab and etesevimab used for this analysis include the authorized doses of 700 mg and 1400 mg or higher (N=1400), or placebo (N=985).

BLAZE-4: Accelerated Infusion Substudy Results

Safety and Tolerability With 15-Minute Infusion

Summary of Adverse Events With 30-Minute and 15-Minute Bamlanivimab and Etesevimab Infusion summarizes the safety of IV administration of undiluted bamlanivimab (20 mL) and undiluted etesevimab (40 mL) added to an empty infusion bag, and infused to patients over 30 or 15 minutes in the BLAZE-4 substudy.

The data from the undiluted treatment arm supported the addition of shorter infusion times added to the Fact Sheet on 09 February 2021.

Summary of Adverse Events With 30-Minute and 15-Minute Bamlanivimab and Etesevimab Infusion8

n (%)a

BAM 700 mg + ETE 1400 mg
30 minutes
(N=6)

BAM 700 mg + ETE 1400 mg
15 minutes
(N=30)

TEAEs

0

3 (10.0)

     Mild

0

2 (6.7)

     Moderate

0

0

     Severe

0

0

     Missing data

0

1 (3.3)

Discontinuation due to AE

0

0

SAEs

0

0

Death

0

0

Abbreviations: % = proportion of patients; AE = adverse event; BAM = bamlanivimab; ETE = etesevimab; SAE = serious adverse event; TEAE = treatment-emergent adverse event.

aNumbers in table represent the number of patients reporting AEs, not number of events.

In the bamlanivimab and etesevimab 15-minute infusion cohort (N = 30), 2 uncoded events were observed. One was defined as an infusion-related reaction and the other defined as shortness of breath/“feeling of infusion” in the chest.8

Enclosed Fact Sheet

Bamlanivimab and Etesevimab Fact Sheet for Health Care Providers

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Fact sheet for healthcare providers. Emergency Use Authorization (EUA) of bamlanivimab and etesevimab. US Food and Drug Administration (FDA). 2021.

2United States Food and Drug Administration. Bamlanivimab and etesevimab FDA Emergency Use Authorization letter. Issued December 22, 2021. Accessed December 22, 2021. http://pi.lilly.com/eua/bam-and-ete-eua-fda-authorization-letter.pdf

3Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632-644. http://dx.doi.org/10.1001/jama.2021.0202

4Dougan M, Azizad M, Mocherla B, et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. Clin Infect Dis. Published online October 28, 2021. http://dx.doi.org/10.1093/cid/ciab912

5Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate covid-19. N Eng J Med. Published online July 14, 2021. http://dx.doi.org/10.1056/NEJMoa2102685

6A study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in participants with mild to moderate COVID-19 illness (BLAZE-1). ClinicalTrials.gov identifier: NCT04427501. Updated September 8, 2021. Accessed September 14, 2021. https://www.clinicaltrials.gov/ct2/show/NCT04427501

7A study of immune system proteins in participants with mild to moderate COVID-19 illness (BLAZE-4). ClinicalTrials.gov identifier: NCT04634409. Updated September 5, 2021. Accessed September 14, 2021. https://clinicaltrials.gov/ct2/show/NCT04634409

8Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

AE = adverse event

ASPR = Assistant Secretary for Preparedness and Response

BAM = bamlanivimab

ETE = etesevimab

COVID-19 = coronavirus disease 2019

EUA = emergency use authorization

FDA = Food and Drug Administration

IV = intravenous

SAE = serious adverse event

SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

TEAE = treatment-emergent adverse event

US = United States

Date of Last Review: December 23, 2021

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly